We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

The International Nocturnal Oxygen (INOX) Trial (INOX)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01044628
Recruitment Status : Active, not recruiting
First Posted : January 8, 2010
Last Update Posted : August 31, 2016
Canadian Institutes of Health Research (CIHR)
Information provided by (Responsible Party):
Yves Lacasse, Laval University

Brief Summary:

Background: Long-term oxygen therapy (LTOT) is the only component of the management of chronic obstructive pulmonary disease (COPD) that improves survival in patients with severe daytime hypoxemia (defined as an arterial oxygen pressure [paO2] measured in stable state <=55 mmHg or in the range 56-59 mmHg when clinical evidence of pulmonary hypertension or polycythemia are noted). In Canada, LTOT is usually provided by a stationary oxygen concentrator and is recommended to be used for at least 15-18 hours a day. Several studies have demonstrated a deterioration in arterial blood gas pressures and oxygen saturation during sleep in patients with COPD. Sleep-related oxygen desaturation often occurs in patients not qualifying for LTOT. The suggestion has been made that the natural progression of COPD to its end stages of chronic pulmonary hypertension, severe hypoxemia, right heart failure, and death is dependent upon the severity of desaturation occurring during sleep. This is an attractive hypothesis and is supported by the fact that hypoxemic episodes during sleep are accompanied by substantial increases in pulmonary arterial pressure and often by important cardiac arrhythmias. Supplemental nocturnal oxygen alleviates both the acute increases in pulmonary arterial pressure and the cardiac arrhythmias. It has been suggested that, over the long run, nocturnal oxygen therapy (N-O2) may halt the progression of long-standing cor pulmonale and prolong survival. Probably due to the fact that the recommendations of scientific societies regarding the indications for and use of N-O2 in COPD not qualifying for conventional LTOT are presently imprecise, a number of patients are currently treated with N-O2 although the beneficial effects of this therapy have not been confirmed.


Primary objective: To determine, in patients with COPD not qualifying for LTOT but who present significant nocturnal arterial oxygen desaturation, whether N-O2 provided for a period of 3 years decreases mortality or delay the prescription of LTOT.

Secondary objectives: To estimate, in the same population, the cost-utility ratio of nocturnal oxygen therapy over a 3-year period.

Hypotheses: In patients with COPD not qualifying for LTOT but who present significant nocturnal arterial oxygen desaturation, N-O2 provided for a period of 3 years is effective in decreasing mortality or delaying the requirement for LTOT; and is cost-effective and favorably compares to other medical interventions.

Research plan:

Study design: We propose a 3-year, multi-center, placebo-controlled, randomized trial of nocturnal oxygen therapy added to usual care in patients presenting sleep-related oxygen desaturation who do not qualify for LTOT.

Inclusion criteria: (1) patients with a diagnosis of COPD supported by an history of past smoking and obstructive disease with FEV1/FVC < 70%; (2) a saturation at rest < 95% ; (3) patients fulfilling our definition of nocturnal oxygen desaturation: >=30% of the recording time with transcutaneous arterial oxygen saturation <90% on at least one of two consecutive recordings.

Intervention: nocturnal oxygen therapy: N-O2 will be delivered overnight to allow the oxygen saturation to be >90%.

Placebo: The patients allocated in the control group will receive room air delivered by defective concentrator. The comparison will be double blind.

Primary outcomes: The primary outcomes of this trial are mortality from all cause or requirement for LTOT (composite outcome).

Secondary outcomes: Secondary outcomes will include quality of life and utility measures, costs from a societal perspective and compliance with oxygen therapy.

Trial duration: The follow-up period lasts at least 3 years. We expect this trial to be completed within 5 years.

Sample size calculation: The sample size should give 90% chance of showing a 30% relative reduction in event rates between the two study groups (i.e., an event rate in the intervention and placebo groups of 28% and 40% respectively). We calculated that 300 patients per group are needed to complete this study (630 to account for potential withdrawal).

Condition or disease Intervention/treatment
Chronic Obstructive Pulmonary Disease Nocturnal Desaturation Device: Concentrator Device: Sham concentrator

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 243 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Outcomes Assessor)
Primary Purpose: Supportive Care
Official Title: Multi-Center Randomized Placebo-controlled Trial of Nocturnal Oxygen Therapy in Chronic Obstructive Pulmonary Disease. The International Nocturnal Oxygen (INOX) Trial
Study Start Date : October 2010
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

MedlinePlus related topics: COPD Oxygen Therapy
U.S. FDA Resources

Arm Intervention/treatment
Active Comparator: Nocturnal oxygen therapy (N-O2)
Oxygen will be delivered overnight to allow the oxygen saturation to be >90%
Device: Concentrator
Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be >90%
Placebo Comparator: Sham concentrator
Sham therapy with ambient air
Device: Sham concentrator
Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.

Primary Outcome Measures :
  1. Composite outcome: all-cause mortality or requirement for continuous oxygen therapy [ Time Frame: Every 2 months ]

Secondary Outcome Measures :
  1. Quality of life [ Time Frame: Once a year ]
  2. Health economics: Costs and health care utilization [ Time Frame: Every 2 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   40 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with a diagnosis of COPD supported by a history of past smoking and obstructive disease: FEV1<70% predicted, FEV1/FVC<70% and a total lung capacity by body plethysmography >80% predicted;
  • Stable COPD at study entry, as demonstrated by (1) no acute exacerbation and (2) no change in medications for at least 6 weeks before enrollment in the trial;
  • Non-smoking patients for at least 6 months before enrollment in the trial;
  • SpO2 at rest < 95%;
  • Patients fulfilling the current definition of nocturnal oxygen desaturation, i.e., >=30% of the recording time with transcutaneous arterial oxygen saturation <90% on at least one of two consecutive recordings;
  • Ability ot give informed consent.

Exclusion Criteria:

  • Patients with severe hypoxemia fulfilling the usual criteria for continuous oxygen therapy at study entry: PaO2 <=55 mmHg; or PaO2 <= 59 mmHg with clinical evidence of at least one of the following: (1) with right ventricular hypertrophy (P pulmonale on ECG:3 mm leads ll, lll, aVf); (2) right ventricular hypertrophy; (3)Peripheral edema (cor pulmonale); (4) hematocrit >=55%;
  • Patients with proven sleep apnea (defined by an apnea/hypopnea index of >=15 events/hour) or suspected sleep apnea on oximetry tracings;
  • Patients currently using nocturnal oxygen therapy;
  • Patients with known left heart or congenital heart diseases, interstitial lung diseases, bronchiectasis as the main cause of obstructive disease, lung carcinoma, severe obesity (body mass index >= 40 kg/m²), or any other disease that could influence survival.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01044628

Canada, Alberta
University of Alberta
Edmonton, Alberta, Canada, T6G 2G8
Canada, British Columbia
Vancouver General Hospital
Vancouver, British Columbia, Canada, V5Z 1M9
Canada, Manitoba
St-Boniface General Hospital
Winnipeg, Manitoba, Canada, R2H 2A6
Canada, New Brunswick
Hôpital Dr Georges-L. Dumont
Moncton, New Brunswick, Canada, E1C 2Z3
Canada, Ontario
Kingston General Hospital
Kingston, Ontario, Canada, K7L 2V7
The Ottawa Hospital (General Campus)
Ottawa, Ontario, Canada, K1H 8L6
Canada, Quebec
Centre de la santé et des services sociaux de Laval (Cité de la Santé de Laval)
Laval, Quebec, Canada, H7V 3Y7
Hôtel-Dieu de Lévis
Lévis, Quebec, Canada, G6V 3Z1
Montreal Chest Institute
Montreal, Quebec, Canada, H3X 2P4
Centre Hospitalier Mount-Sinai
Montreal, Quebec, Canada, H4W 1S7
Institut universitaire de cardiologie et de pneumologie de Québec (IUCPQ)
Québec, Quebec, Canada, G1V 4G5
Hôpital régional de Saint-Jérôme
Saint-Jérôme, Quebec, Canada, J7Z 5T3
CHUS, Fleurimont
Sherbrooke, Quebec, Canada, J1H 5N4
Centre de recherche Pneumomédic inc.
Trois-Rivières, Quebec, Canada, G8T 7A4
Hôpital Nord de Marseille
Marseille, France, 13015
Groupe Hospitalier Pitié - Salpêtrière
Paris, France, 75651 Paris cedex 13
CHU de Poitiers
Poitiers, France, 86000
Centro Hospitalar do Barlavento Algarvio - EPE
Portimao, Algarve, Portugal
Centro Hospitalar de Coimbra
Coimbra, Portugal
Centro Hospitalar da Cova da Beira
Covilha, Portugal
Hospital Pulido Valente - Centro Hospitalar Lisboa Norte
Lisboa, Portugal
Hospital Pedro Hispano Unidade Local de Saude de Matosinhos
Matosinhos, Portugal
Centro Hospitalara Vila Nova de Gaia-Espinho EPE
Vila Nova de Gaia, Portugal
Hospital Galdakao-Usansolo
Galdakao, Biskaia, Spain, 48960
Hospital Universitario de Getafe
Getafe, Spain, 28905
Hospital Universitario 12 de Octubre
Madrid, Spain, 28041
Complexo Hospitalario Universitario de Santiago
Santiago de Compostela, Spain, 15706
Hospital Txagorritxu
Vitoria-Gasteiz, Spain, 01008
Sponsors and Collaborators
Laval University
Canadian Institutes of Health Research (CIHR)
Principal Investigator: Yves Lacasse, MD, MSc Laval University

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Yves Lacasse, Professeur, Laval University
ClinicalTrials.gov Identifier: NCT01044628     History of Changes
Other Study ID Numbers: MCT-99512
First Posted: January 8, 2010    Key Record Dates
Last Update Posted: August 31, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Yves Lacasse, Laval University:
Oxygen therapy

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases